Elderly patients have difficulty with long-term adherence to medications following myocardial infarction, and this is significantly worse among those with kidney dysfunction, according to a study published online January 13 in the Clinical Journal of the American Society of Nephrology, HealthDay News reported.
Elderly patients have difficulty with long-term adherence to medications following myocardial infarction (MI), and this is significantly worse among those with kidney dysfunction, according to a study published online January 13 in the Clinical Journal of the American Society of Nephrology, HealthDay News reported.
Tara I. Chang, MD, of the Stanford University School of Medicine (California) and colleagues examined long-term adherence to medications in a cohort of 2,103 patients aged older than 65 years who were discharged from the hospital after an MI. Patients were treated with one of the recommended medication classes: angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), beta-blockers, and statins. Adherence to these medications was measured by the percentage of days covered for 36 months according to pharmacy refill data.
Long-term adherence to each medication class was poor, investigators found. On average, patients took their medications for only 50% to 60% for all 3 medication classes during the 36-month study period. Additionally, patients who had baseline kidney dysfunction had significantly lower long-term adherence to ACEI/ARB and beta-blockers. Long-term adherence to statins did not vary according to the level of kidney function.
“Future strategies should pay special attention to the elderly with kidney dysfunction because this population may be especially vulnerable to poor long-term medication adherence and its adverse consequences,” the authors wrote.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More